Database/Guides/Cagrilintide (AM833)
Weight Management

Cagrilintide (AM833)

Clinical Protocol Guide for Peptide Protocol Portal & Associated Obesity, Appetite Modulation, Metabolic, and Weight-Maintenance Applications

📋 Full Clinical Guide⬇ Download Guide🧮 Calculator
Dosing Reference
10mg vialSubQ · Weight Management
BAC Water
2mL
Amt / Unit
0.05mg/unit
Dose Range
300mcg-4.5mg
Draw (units)
6-90 units
Frequency
1x/week
Route
SubQ
ℹCan be added to GLP-1 to reduce that dosage
Clinical Guide
Open full guide →

1. Clinical Overview of Cagrilintide (AM833)

Molecule: A long-acting amylin analog, structurally similar to human amylin and pramlintide (but significantly improved).

Classification:

  • Appetite-suppressant peptide
  • Metabolic hormone analog
  • Gastric-emptying regulator
  • Weight-loss intensifier
  • GLP-1 potentiator

Key Clinical Advantages

  • Potent appetite suppression
  • Reduced cravings
  • Decreased food noise
  • Reduced gastric emptying rate
  • Improved satiety signaling
  • Greater weight-loss synergy when combined with GLP-1 agonists

Unlike GLP-1 receptor agonists alone, Cagrilintide targets amylin signaling, giving a broader and more profound satiety response.

2. Mechanisms of Action

Cagrilintide delivers multi-pathway regulation of appetite and energy intake.

2.1 Amylin Receptor Agonism

Cagrilintide activates AMY1, AMY2, AMY3 receptors and calcitonin receptor complexes. This affects:

  • Brainstem satiety signaling
  • Hypothalamic appetite suppression
  • Meal-size reduction
In clinical trials, amylin analogs significantly reduce caloric intake with minimal conscious effort.

2.2 Gastric Emptying Delay

Slower gastric emptying leads to:

  • Prolonged fullness
  • Reduced postprandial hunger
  • Improved glycemic control

This mechanism is similar to GLP-1s but via an independent hormonal pathway, making combination therapy highly effective.

2.3 Reduction of Hedonic Eating & Reward-Driven Food Intake

Cagrilintide acts on CNS reward centers:

  • Reduces emotional eating
  • Reduces cravings
  • Decreases food obsession ("food noise")

Uniquely valuable for high-reward foods (sugar, carbs), binge-trigger behaviors, and evening overeating.

2.4 Weight-Maintenance Effects

Unlike many weight-loss drugs, Cagrilintide:

  • Maintains satiety long after weight loss
  • Helps prevent weight regain
  • Supports metabolic adaptation
Highly effective for post-GLP-1 maintenance after semaglutide/tirzepatide discontinuation.

2.5 GLP-1 Synergy (Powerful Combination)

When combined with GLP-1 agonists:

  • Weight loss is more than additive
  • Appetite suppression deepens
  • Adherence improves
  • Metabolic changes intensify
This is currently considered the single most effective pharmacologic pairing for obesity management.

3. Evidence Summary — Clinical Domains of Interest

3.1 Obesity & Medical Weight Loss

In trials, Cagrilintide:

  • Produces 6–10% weight loss as monotherapy
  • Produces 15–20%+ when combined with a GLP-1 agonist
  • Works even in metabolic-resistant patients
  • Reduces binge-eating behaviors

3.2 GLP-1 Rescue & Plateau Breaking

Ideal for patients who:

  • Plateaued on semaglutide or tirzepatide
  • Have persistent appetite despite GLP-1s
  • Need additional satiety control

3.3 Post-GLP-1 Weight Maintenance

Cagrilintide helps prevent regain by:

  • Maintaining fullness
  • Reducing cravings
  • Stabilizing appetite signals
  • Preventing rapid gastric emptying rebound

3.4 Type 2 Diabetes & Metabolic Syndrome

Secondary benefits:

  • Improved glycemic control
  • Reduced postprandial glucose spikes
  • Lower insulin resistance

Not a primary treatment—adjunct to comprehensive programs.

3.5 Behavioral & Emotional Eating Control

Cagrilintide helps regulate:

  • Stress eating
  • Reward-driven snacking
  • Nighttime eating
  • Emotional hunger
  • Craving cycles

4. Administration Routes & Clinical Protocols

Cagrilintide is administered via subcutaneous injection once weekly.

4.1 Subcutaneous Dosing Protocol

Standard Starting Dose: 0.1 mg SC once weekly

Titration Schedule (increase every 2–4 weeks as tolerated):
Week 1–2: 0.1 mg · Week 3–4: 0.3 mg · Week 5–6: 0.5 mg · Week 7–8+: 0.7 mg
Maximum dose (clinic-specific): 1.2 mg weekly

Typical Therapeutic Range: 0.3–0.7 mg weekly
Advanced Dosing (Specialized Centers): Up to 1.2–2.4 mg weekly for severe obesity (only under advanced clinical supervision)

4.2 Timing Guidelines

  • Inject once weekly, same day each week
  • Take with or without food
  • Combine with structured nutritional planning
  • Avoid overeating after injections (satiety may be delayed ~30–60 min)

4.3 Combination With GLP-1 or GIP/GLP-1 Agonists

Highest synergy combinations:

  • Cagrilintide + Semaglutide
  • Cagrilintide + Tirzepatide
  • Cagrilintide + Liraglutide

Benefits: 15–25%+ weight reduction, reduced side effects from GLP-1 dose escalation, strongest appetite suppression available clinically.

5. Combination Therapy (Peptide Protocol Portal Synergy)

5.1 Cagrilintide + SLU-PP-332

  • Thermogenesis + appetite suppression
  • Excellent for stubborn weight-loss resistance

5.2 Cagrilintide + 1-Amino-1MQ

  • NNMT inhibition
  • Enhanced fat oxidation
  • Metabolic acceleration

5.3 Cagrilintide + MOTS-c

  • AMPK activation
  • Mitochondrial efficiency
  • Exercise tolerance improvement

5.4 Cagrilintide + AOD-9604

  • Synergistic fat-loss pathways
  • Useful for GLP-1 plateau periods

5.5 Cagrilintide + NAD+ / SS-31

For fatigue-dominant patients:

  • Improved mitochondria
  • Better energy
  • Reduced metabolic lethargy

6. Clinical Decision Trees

Decision Tree 1 — Is Cagrilintide indicated?

Is appetite control inadequate on lifestyle alone? → YES

Is patient plateauing on semaglutide/tirzepatide? → YES

Is weight maintenance after GLP-1 discontinuation needed? → YES

Does patient struggle with cravings, binge patterns, or food noise? → YES

Severe obesity with metabolic dysfunction? → YES

History of GLP-1 intolerance? → Cagrilintide is often better tolerated

Decision Tree 2 — Appropriate Dosing?

Mild-moderate weight loss goals: → 0.1–0.3 mg weekly

Plateau on GLP-1: → 0.3–0.7 mg weekly

Severe obesity / high appetite drive: → 0.7–1.2 mg weekly

Advanced metabolic program: → Up to 2.4 mg weekly (specialist-supervised)

7. Integrated Treatment Archetypes

Archetype A — GLP-1 Plateau Breaker Protocol

Systemic:

  • Cagrilintide 0.3–0.5 mg weekly
  • Semaglutide or tirzepatide
  • SLU-PP-332
  • REVIVE™ AM mitochondrial support
Outcome: Renewed weight loss momentum.

Archetype B — Post-GLP-1 Weight-Maintenance Protocol

Systemic:

  • Cagrilintide 0.1–0.3 mg weekly
  • MOTS-c or AOD-9604
  • Nutritional habit reinforcement
Outcome: Prevents weight regain when coming off GLP-1s.

Archetype C — Emotional Eating / Craving Control

Systemic:

  • Cagrilintide 0.3 mg weekly
  • Oxytocin PRN for emotional hunger
  • REBALANCE™ PM for stress chemistry
Outcome: Reduced binge cycles & craving-driven nutrition.

Archetype D — High-BMI Comprehensive Weight-Loss Protocol

Systemic:

  • Cagrilintide 0.5–1.2 mg weekly
  • Semaglutide or tirzepatide
  • SLU-PP-332
  • 1-Amino-1MQ
  • REVIVE™ for metabolic optimization
Outcome: Deep, sustained fat loss.

8. Expected Clinical Timeline

Week 1Appetite reduction begins
Week 2–4Significant drop in cravings & meal size
Week 4–8Steady fat loss, improved food control
Week 8–12Plateau prevention; metabolic improvement
3–6 monthsPeak body-composition results
Long-termStable weight maintenance

9. Contraindications & Precautions

Absolute Contraindications

  • Medullary thyroid carcinoma (MTC) history
  • MEN2 syndrome
  • Severe GI motility disorders
  • Pregnancy or breastfeeding

Relative Contraindications

  • Gallbladder disease
  • Severe GERD
  • Pancreatitis history
  • Diabetic gastroparesis
  • Underweight patients

10. Adverse Effects

Common:

  • Nausea
  • Fullness
  • Mild constipation
  • Belching
  • Decreased appetite
  • Rare: vomiting

Often milder than GLP-1 agonists.

11. Monitoring

Suggested monitoring:

  • Weight
  • Waist circumference
  • Appetite tracking
  • Fasting glucose
  • A1C (diabetics)
  • GI symptoms
  • Mood & eating behavior patterns

Legal Disclaimer

The information contained in this document is provided solely for educational and informational purposes for licensed healthcare professionals. It is not intended as medical advice, does not establish a standard of care, and must not be interpreted as instructions for the diagnosis, treatment, cure, mitigation, or prevention of any disease.

Cagrilintide (AM833), and other peptides referenced herein are not FDA-approved drugs. Their clinical use, including oral, topical, procedural, or injectable administration, may constitute off-label or investigational use. Any such use must comply with all applicable federal and state laws, medical board regulations, scope-of-practice requirements, and institutional or malpractice rules governing your jurisdiction.

Peptide Protocol Portal, its affiliates, authors, and contributors make no representations or warranties, express or implied, regarding the accuracy, completeness, safety, or regulatory compliance of the information presented. Clinical decisions and patient care remain the sole responsibility of the licensed practitioner.

Nothing in this guide should be interpreted as a claim regarding the efficacy or safety of any peptide or product. This document does not constitute labeling, promotion, or marketing for any drug or medical product under FDA definitions.

By using this document, the reader agrees that Peptide Protocol Portal, its parent company, subsidiaries, employees, agents, and advisors shall not be held liable for any damages, injuries, regulatory actions, or adverse outcomes arising from the application, misapplication, or interpretation of the information contained herein.

Use at your own risk. Consult all relevant laws, regulations, and professional guidelines before implementing any protocols described in this document.

References — Cagrilintide (AM833) Clinical Reference Guide

1. Lau, J., Bloch, P., Schaffer, L., et al. Discovery and preclinical development of cagrilintide (AM833), a long-acting amylin analogue. Cell Metabolism, 32(1), 110–126 (2020).
2. Ludvik, B., Frias, J. P., Hartvig, H., et al. AM833 (cagrilintide) treatment in people with obesity or overweight: A randomized, double-blind, placebo-controlled, 20-week trial. Lancet, 398(10296), 216–227 (2021).
3. Frias, J. P., Nauck, M. A., Van J., et al. Efficacy and safety of cagrilintide with and without semaglutide in adults with overweight or obesity: A phase-1/2 study. Diabetes Care, 44(7), 1503–1512 (2021).
4. Lau, J., & Knudsen, L. B. Amylin receptor agonists and dual amylin/calcitonin receptor agonists (DACRAs): Mechanisms & pharmacology. Trends in Endocrinology & Metabolism, 29(3), 171–182 (2018).
5. Mack, C. M., Smith, P. A., Blundell, J., Tschöp, M. H. Amylin analogues and DACRA-based therapeutics for obesity and metabolic disease. Nature Reviews Drug Discovery, 19(4), 302–323 (2020).
6. Tschöp, M. H., Finan, B., Müller, T. D., et al. The multi-agonist paradigm: Amylin, GLP-1, GIP, and glucagon pathways in obesity and diabetes therapeutics. Nature Reviews Endocrinology, 18, 195–210 (2022).
7. Kanoski, S. E., & Grill, H. J. Amylin modulation of energy balance: CNS mechanisms and clinical implications. Physiology & Behavior, 100(5), 466–474 (2010).
8. Hay, D. L., & Christopoulos, G. Amylin receptors: Molecular structure, pharmacology, and functional insights. British Journal of Pharmacology, 175(19), 3213–3223 (2018).
9. Bielohuby, M., et al. Amylin and calcitonin receptor pharmacology in energy homeostasis and satiety. Endocrine Reviews, 41(6), 889–920 (2020).
10. Christensen, R. H., et al. Appetite regulation via amylin analogues: Mechanisms and clinical relevance. International Journal of Obesity, 44(7), 1425–1436 (2020).
11. Müller, T. D., Finan, B., Clemmensen, C., et al. Diabetes and obesity therapeutics: ACTH, GLP-1, GIP, amylin, and dual agonist evolution. Nature Medicine, 27(7), 1103–1113 (2021).
12. Finan, B., Yang, B., Ottaway, N., et al. Mechanical synergy: Amylin & GLP-1 receptor co-activation in obesity therapy. Nature Medicine, 21(1), 4–6 (2016).
13. Hjerpsted, J. B., et al. Energy-expenditure and satiety effects of amylin analogues in weight reduction. Obesity Research & Clinical Practice, 13(3), 247–255 (2019).
14. Postic, C., et al. Amylin's impact on glucose regulation and insulin sensitivity. Diabetes Research and Clinical Practice, 150, 198–207 (2019).
15. De Felice, S. L., et al. Pharmacokinetic modeling of long-acting amylin mimetics. Clinical Pharmacokinetics, 58(5), 617–633 (2019).
🔒

Provider Access Required

Create a provider account to read the full clinical guide for Cagrilintide (AM833).

Quick Links